Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Stomach Neoplasms × zanidatamab × Clear all

Phase

Status

Sponsor Class

INDUSTRY 5 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 Stomach Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Neoplasms 1 Muscle Invasive Bladder Cancer (MIBC) 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 182 Capecitabine 107 Fluorouracil 97 S 1 (combination) 96 Docetaxel 93 Cisplatin 78 Leucovorin 71 Paclitaxel 67 Irinotecan 64 apatinib 42 Drug Therapy 39 sintilimab 35 Surgical Procedures, Operative 34 Hyperthermic Intraperitoneal Chemotherapy 31 Radiotherapy 30 pembrolizumab 28 Trastuzumab 27 Gastrectomy 21 Tegafur 20 Epirubicin 20 XELOX 19 Nivolumab 19 Bevacizumab 19 camrelizumab 17 titanium silicide 16 tislelizumab 16 Ramucirumab 16 Carboplatin 16 Cetuximab 13 Albumin-Bound Paclitaxel 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07176312 2026-02-04

ZANGEA

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Recruiting

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡